Clinical trial · Observational
Blastic Plasmacytoid Dendritic Cell Neoplasm in Korean Population.
Blastic Plasmacytoid Dendritic Cell Neoplasm in Korean Population: A Multicenter Study
NCT03974971CI-TRIAL-00046945KBPDCNcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Retrospective study , To analyze the clinical features and treatment outcomes in Korean blastic plasmacytoid dendritic cell neoplasm.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Blastic Plasmacytoid Dendritic Cell Neoplasm | Blastic Plasmacytoid Dendritic Cell Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- BPDCN diagnosis group
- description
- By review medical records Enroll patients diagnosed with BPDCN from January 1, 2000 to October 31, 2018
Primary outcomes (1)
- measure
- Overall Survival Rate
- timeFrame
- from the date of the IRB approval until June 30, 2019
- description
- From the date of diagnosis to the date of death, or from the date of diagnosis to the last follow-up date.
Secondary outcomes (3)
- measure
- Therapeutic Response Rate
- timeFrame
- from the date of the IRB approval until June 30, 2019
- description
- Therapeutic response analysis is based on the evaluation of the response of common leukemia and lymphoma
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
\<Inclusion Criteria\> 1. Patients ≥ 18 years 2. Pathologically confirmed diagnosis by tissue or bone marrow at each center with * Blastic plasmacytoid dendritic cell neoplasm * Blastic NK-cell lymphoma * Agranular CD4+ natural killer cell leukaemia * Blastic natural killer leukaemia/lymphoma * Agranular CD4+CD56+ haematodermic neoplasm/tumour 3. Antigen expression of CD4 and/or CD56 coupled with at least one plasmacytoid dendritic cell-associated antigen among CD123, TCL1, CD2AP and BDCA2/CD303 \<Exclusion Criteria\> 1. Acute myeloid leukemia 2. Acute lymphoblastic leukemia 3. Mixed phenotype acute leukemia 4. Any type of B- or T-/NK/T-cell lymphomas 5. Expression of lineage-specific markers for B cells (CD20, CD79a) T cells (CD3) Myeloid cells (myeloperoxidase) Monocytes (CD11c, CD163, lysozyme). CD34
References
Publications (0)
Data not yet available
No reference posted for this study.